Management of ankylosing spondylitis with infliximab

Éric Toussirot1,2,3, Ewa Bertolini1, Daniel Wendling1,21Rheumatology, University Hospital Jean Minjoz, Besançon, France; 2Equipe d’Accueil 3186 “Agents pathogènes et Inflammation” University of Franche-Comt&am...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Éric Toussirot, Ewa Bertolini, Daniel Wendling
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/f7446406be53441a95382372855bd969
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f7446406be53441a95382372855bd969
record_format dspace
spelling oai:doaj.org-article:f7446406be53441a95382372855bd9692021-12-02T07:16:42ZManagement of ankylosing spondylitis with infliximab1179-156Xhttps://doaj.org/article/f7446406be53441a95382372855bd9692009-06-01T00:00:00Zhttp://www.dovepress.com/management-of-ankylosing-spondylitis-with-infliximab-a3271https://doaj.org/toc/1179-156XÉric Toussirot1,2,3, Ewa Bertolini1, Daniel Wendling1,21Rheumatology, University Hospital Jean Minjoz, Besançon, France; 2Equipe d’Accueil 3186 “Agents pathogènes et Inflammation” University of Franche-Comté, Besançon, France; 3CiC – Biotherapy, St-Jacques Hospital, Besançon, FranceAbstract: Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease responsible for back pain, stiffness and progressive loss of  functional capacity with limited therapeutic options. Regular physical exercises together with the use of nonsteroidal antiinflammatory drugs are the two recognized treatment options in AS. Infliximab is a chimeric anti-tumor necrosis factor-α monoclonal antibody that has been demonstrated to be highly effective in the treatment of AS, providing clinical amelioration at both axial and peripheral skeleton. Infliximab also improves quality of life, function, biological parameters (acute phase reactants) and inflammatory lesions of the spine as detected by magnetic resonance imaging. It is given at a 5 mg/kg dosage, as an infusion at weeks 0, 2, 6, and every 6 to 8 weeks after. Open-label and placebo-controlled trials have well demonstrated its high level of efficacy, with an improvement of the disease activity of at least 50% in 60%–80% of patients. In a large placebo-controlled trial, Assessment in Ankylosing Spondylitis Response Criteria (ASAS20) responders were observed in 61.2% of patients receiving infliximab compared to 19.2% of patients under placebo. Long-term efficacy is maintained when infliximab is administered every 6–8 weeks. Consensus international guidelines for the initiation and the use of this expensive treatment are available. Some questions remain, including the long-term safety, in particular the risk of lymphoma, and the potential influence of infliximab on radiological progression which is not currently demonstrated. Despite these concerns, infliximab has revolutionized the management of AS and represents a considerable therapeutic advancement in this disabling disease.Keywords: anti-TNFα, infliximab, ankylosing spondylitis Éric ToussirotEwa BertoliniDaniel WendlingDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2009, Iss default, Pp 69-82 (2009)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the musculoskeletal system
RC925-935
spellingShingle Diseases of the musculoskeletal system
RC925-935
Éric Toussirot
Ewa Bertolini
Daniel Wendling
Management of ankylosing spondylitis with infliximab
description Éric Toussirot1,2,3, Ewa Bertolini1, Daniel Wendling1,21Rheumatology, University Hospital Jean Minjoz, Besançon, France; 2Equipe d’Accueil 3186 “Agents pathogènes et Inflammation” University of Franche-Comté, Besançon, France; 3CiC – Biotherapy, St-Jacques Hospital, Besançon, FranceAbstract: Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease responsible for back pain, stiffness and progressive loss of  functional capacity with limited therapeutic options. Regular physical exercises together with the use of nonsteroidal antiinflammatory drugs are the two recognized treatment options in AS. Infliximab is a chimeric anti-tumor necrosis factor-α monoclonal antibody that has been demonstrated to be highly effective in the treatment of AS, providing clinical amelioration at both axial and peripheral skeleton. Infliximab also improves quality of life, function, biological parameters (acute phase reactants) and inflammatory lesions of the spine as detected by magnetic resonance imaging. It is given at a 5 mg/kg dosage, as an infusion at weeks 0, 2, 6, and every 6 to 8 weeks after. Open-label and placebo-controlled trials have well demonstrated its high level of efficacy, with an improvement of the disease activity of at least 50% in 60%–80% of patients. In a large placebo-controlled trial, Assessment in Ankylosing Spondylitis Response Criteria (ASAS20) responders were observed in 61.2% of patients receiving infliximab compared to 19.2% of patients under placebo. Long-term efficacy is maintained when infliximab is administered every 6–8 weeks. Consensus international guidelines for the initiation and the use of this expensive treatment are available. Some questions remain, including the long-term safety, in particular the risk of lymphoma, and the potential influence of infliximab on radiological progression which is not currently demonstrated. Despite these concerns, infliximab has revolutionized the management of AS and represents a considerable therapeutic advancement in this disabling disease.Keywords: anti-TNFα, infliximab, ankylosing spondylitis
format article
author Éric Toussirot
Ewa Bertolini
Daniel Wendling
author_facet Éric Toussirot
Ewa Bertolini
Daniel Wendling
author_sort Éric Toussirot
title Management of ankylosing spondylitis with infliximab
title_short Management of ankylosing spondylitis with infliximab
title_full Management of ankylosing spondylitis with infliximab
title_fullStr Management of ankylosing spondylitis with infliximab
title_full_unstemmed Management of ankylosing spondylitis with infliximab
title_sort management of ankylosing spondylitis with infliximab
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/f7446406be53441a95382372855bd969
work_keys_str_mv AT ampeacuterictoussirot managementofankylosingspondylitiswithinfliximab
AT ewabertolini managementofankylosingspondylitiswithinfliximab
AT danielwendling managementofankylosingspondylitiswithinfliximab
_version_ 1718399553940488192